Alluvi, previously BI 4744, presents a promising development in obesity treatment. This dual agonist targeting both GLP-1 and GIP receptors demonstrates impressive efficacy in research trials, potentially outperforming https://bookmarketmaven.com/story23045626/alluvi-a-in-depth-investigation-into-the-retatrutide-s-prospects